Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

Healthcare utilization and management of actinic keratosis in primary and secondary care: a complementary database analysis.

Noels EC, Hollestein LM, van Egmond S, Lugtenberg M, van Nistelrooij LPJ, Bindels PJE, van der Lei J, Stern RS, Nijsten T, Wakkee M.

Br J Dermatol. 2019 Jan 12. doi: 10.1111/bjd.17632. [Epub ahead of print]

PMID:
30636037
2.

Essentials for a successful registry: valid data, the right questions and timely execution.

Garcia-Doval I, Stern RS.

Br J Dermatol. 2018 Oct;179(4):805-806. doi: 10.1111/bjd.16987. No abstract available.

PMID:
30318796
3.

Reduced-Intensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell Transplantation.

Wu PA, Stern RS, Huang V, Liu KX, Chen CA, Tzachanis D, Joyce RM, Davis RB, Ho VT.

J Invest Dermatol. 2019 Mar;139(3):591-599. doi: 10.1016/j.jid.2018.08.025. Epub 2018 Oct 11.

PMID:
30316899
4.

Local radiation and phototherapy are the most cost-effective treatments for stage IA mycosis fungoides: A comparative decision analysis model in the United States.

Xia FD, Ferket BS, Huang V, Stern RS, Wu PA.

J Am Acad Dermatol. 2019 Feb;80(2):485-492.e4. doi: 10.1016/j.jaad.2018.07.040. Epub 2018 Aug 3.

PMID:
30081119
5.

Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland.

Garcia-Doval I, Descalzo MA, Mason KJ, Cohen AD, Ormerod AD, Gómez-García FJ, Cazzaniga S, Feldhamer I, Ali H, Herrera-Acosta E, Griffiths CEM, Stern RS, Naldi L; Psonet Network.

Br J Dermatol. 2018 Oct;179(4):863-871. doi: 10.1111/bjd.16715. Epub 2018 Jul 24.

PMID:
29723914
6.

Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.

Busard CI, Cohen AD, Wolf P, Gkalpakiotis S, Cazzaniga S, Stern RS, Hutten BA, Feldhamer I, Quehenberger F, Lichem R, Kojanova M, Adenubiova E, Addis A, Naldi L, Spuls PI.

J Eur Acad Dermatol Venereol. 2018 Feb;32(2):245-253. doi: 10.1111/jdv.14583. Epub 2017 Oct 17.

PMID:
28898541
7.

'Whoever has will be given more' (Matthew 13:12): authorship of systematic reviews and clinical trials in the biological age.

Stern RS.

Br J Dermatol. 2017 Jun;176(6):1422-1424. doi: 10.1111/bjd.15568. No abstract available. Erratum in: Br J Dermatol. 2018 Mar;178(3):815.

PMID:
28581224
8.
9.

Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries.

Davila-Seijo P, Garcia-Doval I, Naldi L, Cazzaniga S, Augustin M, Rustenbach SJ, Daudén E, Dam TN, Baker C, Spuls PI, Stern RS, Cohen AD.

Acta Derm Venereol. 2017 Apr 6;97(4):516-518. doi: 10.2340/00015555-2586. No abstract available.

10.

Presence of Hand Warts Is Associated with Subsequent Development of Cutaneous Squamous Cell Carcinoma in Psoriasis Patients Treated with Psoralen UVA (PUVA).

Wu PA, Chen CA, Stern RS.

J Invest Dermatol. 2016 Nov;136(11):2317-2319. doi: 10.1016/j.jid.2016.07.010. Epub 2016 Jul 22. No abstract available.

11.

Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries.

Garcia-Doval I, Cohen AD, Cazzaniga S, Feldhamer I, Addis A, Carretero G, Ferrándiz C, Stern RS, Naldi L; Psonet Network.

J Am Acad Dermatol. 2017 Feb;76(2):299-308.e16. doi: 10.1016/j.jaad.2016.07.039. Epub 2016 Sep 29.

PMID:
27693008
12.

How likely is another nonmelanoma skin cancer?: better informing patients and clinicians.

Wu PA, Stern RS.

JAMA Dermatol. 2015 Apr;151(4):369-70. doi: 10.1001/jamadermatol.2014.3827. No abstract available.

PMID:
25587795
13.

Recurrence of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Stern RS.

JAMA. 2014 Oct 15;312(15):1590-1. doi: 10.1001/jama.2014.10777. No abstract available.

PMID:
25321917
14.

Suicidal ideation, mental health problems, and social function in adolescents with eczema: a population-based study.

Halvorsen JA, Lien L, Dalgard F, Bjertness E, Stern RS.

J Invest Dermatol. 2014 Jul;134(7):1847-1854. doi: 10.1038/jid.2014.70. Epub 2014 Feb 4.

15.

Response to Rogers et al.

Stern RS.

J Invest Dermatol. 2014 Apr;134(4):1136-1137. doi: 10.1038/jid.2013.451. Epub 2013 Oct 30. No abstract available.

16.

Cost effectiveness of Mohs micrographic surgery.

Stern RS.

J Invest Dermatol. 2013 May;133(5):1129-31. doi: 10.1038/jid.2012.473.

17.

Telaprevir-related dermatitis.

Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, Bengtsson L, Singhal P, Kauffman RS, Stern RS.

JAMA Dermatol. 2013 Feb;149(2):152-8.

PMID:
23560295
18.

Impact of bar-code labeling of clinical photographs on patient care and practice workflow.

Cukras AR, Stern RS.

Arch Dermatol. 2012 Nov;148(11):1327-9. doi: 10.1001/archdermatol.2012.2901. No abstract available.

PMID:
23165848
19.

Clinical practice. Exanthematous drug eruptions.

Stern RS.

N Engl J Med. 2012 Jun 28;366(26):2492-501. doi: 10.1056/NEJMcp1104080. Review. No abstract available.

PMID:
22738099
20.

Topical tretinoin, another failure in the pursuit of practical chemoprevention for non-melanoma skin cancer.

Wu PA, Stern RS.

J Invest Dermatol. 2012 Jun;132(6):1532-5. doi: 10.1038/jid.2012.136.

21.

Going beyond associative studies of psoriasis and cardiovascular disease.

Stern RS, Nijsten T.

J Invest Dermatol. 2012 Mar;132(3 Pt 1):499-501. doi: 10.1038/jid.2011.452. No abstract available.

22.

The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study.

Stern RS; PUVA Follow-Up Study.

J Am Acad Dermatol. 2012 Apr;66(4):553-62. doi: 10.1016/j.jaad.2011.04.004. Epub 2012 Jan 20.

PMID:
22264671
23.

How epidemiology has contributed to a better understanding of skin disease.

Nijsten T, Stern RS.

J Invest Dermatol. 2012 Mar;132(3 Pt 2):994-1002. doi: 10.1038/jid.2011.372. Epub 2011 Dec 8. Review.

24.

Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study.

Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB, Stern RS.

J Invest Dermatol. 2011 Jul;131(7):1460-8. doi: 10.1038/jid.2011.58. Epub 2011 Mar 10.

25.

Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk.

Stern RS, Huibregtse A.

J Invest Dermatol. 2011 May;131(5):1159-66. doi: 10.1038/jid.2010.399. Epub 2011 Jan 20.

26.

Poor metrics and lost opportunity.

Stern RS.

J Am Acad Dermatol. 2010 Oct;63(4):718-9. doi: 10.1016/j.jaad.2010.05.028. No abstract available.

PMID:
20846572
27.

Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study.

Halvorsen JA, Stern RS, Dalgard F, Thoresen M, Bjertness E, Lien L.

J Invest Dermatol. 2011 Feb;131(2):363-70. doi: 10.1038/jid.2010.264. Epub 2010 Sep 16.

28.

Psoriasis is not a useful independent risk factor for cardiovascular disease.

Stern RS.

J Invest Dermatol. 2010 Apr;130(4):917-9. doi: 10.1038/jid.2009.446.

29.

Prevalence of a history of skin cancer in 2007: results of an incidence-based model.

Stern RS.

Arch Dermatol. 2010 Mar;146(3):279-82. doi: 10.1001/archdermatol.2010.4.

PMID:
20231498
30.

How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review.

Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T.

J Invest Dermatol. 2010 Apr;130(4):933-43. doi: 10.1038/jid.2009.391. Epub 2009 Dec 31. Review.

31.

The misperception that clinical trial data reflect long-term drug safety: lessons learned from Efalizumab's withdrawal.

Nijsten T, Spuls PI, Naldi L, Stern RS.

Arch Dermatol. 2009 Sep;145(9):1037-9. doi: 10.1001/archdermatol.2009.188. No abstract available.

PMID:
19770445
32.

Putting iatrogenic risk in perspective: basal cell cancer in PUVA patients and Australians.

Stern RS.

J Invest Dermatol. 2009 Sep;129(9):2315-6. doi: 10.1038/jid.2009.36. Epub 2009 Mar 5. No abstract available.

33.

National registries of systemic treatment for psoriasis and the European 'Psonet' initiative.

Lecluse LL, Naldi L, Stern RS, Spuls PI.

Dermatology. 2009;218(4):347-56. doi: 10.1159/000183757. Epub 2008 Dec 11.

PMID:
19077384
34.

STROBE: a Beacon for observational studies.

Nijsten T, Spuls P, Stern RS.

Arch Dermatol. 2008 Sep;144(9):1200-4. doi: 10.1001/archderm.144.9.1200. No abstract available.

PMID:
18794467
35.

Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.

Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, Birgersdotter-Green UM, Wathen MS, Van Gelder IC, Heubner BM, Brown ML, Holloman KK; PREPARE Study Investigators.

J Am Coll Cardiol. 2008 Aug 12;52(7):541-50. doi: 10.1016/j.jacc.2008.05.011.

36.

Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis.

Pirmohamed M, Arbuckle JB, Bowman CE, Brunner M, Burns DK, Delrieu O, Dix LP, Twomey JA, Stern RS.

Pharmacogenomics. 2007 Dec;8(12):1661-91.

PMID:
18085998
37.
38.

The reduced Impact of Psoriasis Questionnaire has good psychometric properties in Italian patients.

Nijsten T, Sampogna F, Stern RS, Abeni D.

Dermatology. 2007;215(4):348-51.

PMID:
17911994
39.

Clinical severity of psoriasis in last 20 years of PUVA study.

Nijsten T, Looman CW, Stern RS.

Arch Dermatol. 2007 Sep;143(9):1113-21.

PMID:
17875871
40.

Psoralen and ultraviolet a light therapy for psoriasis.

Stern RS.

N Engl J Med. 2007 Aug 16;357(7):682-90. Review. No abstract available.

PMID:
17699818
41.

Use of biological agents in patients with moderate to severe psoriasis: a cohort-based perspective.

Jones-Caballero M, Unaeze J, Peñas PF, Stern RS.

Arch Dermatol. 2007 Jul;143(7):846-50.

PMID:
17638727
42.

Reported use of photosensitizing medications and basal cell and squamous cell carcinoma of the skin: results of a population-based case-control study.

Karagas MR, Stukel TA, Umland V, Tsoukas MM, Mott LA, Sorensen HT, Jensen AO, Nelson HH, Spencer SK, Perry AE, Stern RS.

J Invest Dermatol. 2007 Dec;127(12):2901-3. Epub 2007 Jun 28. No abstract available.

43.

Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study.

Malanos D, Stern RS.

J Am Acad Dermatol. 2007 Aug;57(2):231-7. Epub 2007 May 25.

PMID:
17532094
44.

Topical calcineurin inhibitors labeling: putting the "box" in perspective.

Stern RS.

Arch Dermatol. 2006 Sep;142(9):1233-5. No abstract available.

PMID:
16983018
45.

Lymphoma risk in psoriasis: results of the PUVA follow-up study.

Stern RS.

Arch Dermatol. 2006 Sep;142(9):1132-5.

PMID:
16983000
46.

Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi.

Gimnig JE, MacArthur JR, M'bang'ombe M, Kramer MH, Chizani N, Stern RS, Mkandala C, Newman RD, Steketee RW, Campbell CH.

Am J Trop Med Hyg. 2006 May;74(5):738-43.

PMID:
16687672
47.

Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study.

Unaeze J, Nijsten T, Murphy A, Ravichandran C, Stern RS.

J Invest Dermatol. 2006 Jul;126(7):1480-9. Epub 2006 Mar 30.

48.

Refinement and reduction of the Impact of Psoriasis Questionnaire: classical test theory vs. Rasch analysis.

Nijsten T, Unaeze J, Stern RS.

Br J Dermatol. 2006 Apr;154(4):692-700.

PMID:
16536813
49.

Epidemiology of psoriatic arthritis in the population of the United States.

Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, Rolstad T.

J Am Acad Dermatol. 2005 Oct;53(4):573.

PMID:
16198775
50.

The psychometric properties of the psoriasis disability index in United States patients.

Nijsten T, Whalley D, Gelfand J, Margolis D, McKenna SP, Stern RS.

J Invest Dermatol. 2005 Oct;125(4):665-72.

Supplemental Content

Loading ...
Support Center